Early exposure, enduring consequences: How do I manage Rh immunoglobulin prophylaxis after Rh-mismatched transfusions in children?

Background: RhD mismatched transfusions in RhD negative women have the potential to impact future pregnancies through alloimmunization and development of hemolytic disease of the fetus and newborn (HDFN). As use of RhD positive emergency-release blood products in pediatric trauma has increased, it has become clear that a significant alloimmunization risk also exists for RhD negative girls, which has not been addressed by existing literature. This article describes a best-practice guideline to manage RhD negative pediatric females who receive RhD positive transfusions. Design: Pathology or transfusion medicine staff are notified of RhD-mismatched blood transfusions and eligibility for therapy with RhIG is determined. Patients are evaluated by Pediatrics or Pediatric Hematology. These consultants will provide counseling and offer treatment. Results: Management strategy depends on red blood cell volume (RBCv) transfused. Pediatric females who receive RBCv <20% of their TBV are eligible to receive RhIG, while those who receive >20% are not. Unlike in adult females, TBV calculations change with age. All should be screened for the development of anti-D antibodies between 6 and 12 months after transfusion, regardless of treatment with RhIG. When the patient reaches adulthood, she should be followed by ObGyn and undergo repeat antibody testing before becoming pregnant. Conclusion: Protocols for the management of mismatched transfusions in RhD negative women have been established, but there are no published guidelines directing management of similar pediatric patients. The described approach provides a safe and effective framework to mitigate RhD alloimmunization risk for these pediatric patients, thereby safeguarding their future reproductive outcomes.